EMBO Molecular Medicine (May 2022)

S1P defects cause a new entity of cataract, alopecia, oral mucosal disorder, and psoriasis‐like syndrome

  • Fuying Chen,
  • Cheng Ni,
  • Xiaoxiao Wang,
  • Ruhong Cheng,
  • Chaolan Pan,
  • Yumeng Wang,
  • Jianying Liang,
  • Jia Zhang,
  • Jinke Cheng,
  • Y Eugene Chin,
  • Yi Zhou,
  • Zhen Wang,
  • Yiran Guo,
  • She Chen,
  • Stephanie Htun,
  • Erin F Mathes,
  • Alejandra G de Alba Campomanes,
  • Anne M Slavotinek,
  • Si Zhang,
  • Ming Li,
  • Zhirong Yao

DOI
https://doi.org/10.15252/emmm.202114904
Journal volume & issue
Vol. 14, no. 5
pp. n/a – n/a

Abstract

Read online

Abstract In this report, we discovered a new entity named cataract, alopecia, oral mucosal disorder, and psoriasis‐like (CAOP) syndrome in two unrelated and ethnically diverse patients. Furthermore, patient 1 failed to respond to regular treatment. We found that CAOP syndrome was caused by an autosomal recessive defect in the mitochondrial membrane‐bound transcription factor peptidase/site‐1 protease (MBTPS1, S1P). Mitochondrial abnormalities were observed in patient 1 with CAOP syndrome. Furthermore, we found that S1P is a novel mitochondrial protein that forms a trimeric complex with ETFA/ETFB. S1P enhances ETFA/ETFB flavination and maintains its stability. Patient S1P variants destabilize ETFA/ETFB, impair mitochondrial respiration, decrease fatty acid β‐oxidation activity, and shift mitochondrial oxidative phosphorylation (OXPHOS) to glycolysis. Mitochondrial dysfunction and inflammatory lesions in patient 1 were significantly ameliorated by riboflavin supplementation, which restored the stability of ETFA/ETFB. Our study discovered that mutations in MBTPS1 resulted in a new entity of CAOP syndrome and elucidated the mechanism of the mutations in the new disease.

Keywords